Related Experiment Video
Updated: Jul 15, 2025
08:08
Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
Published on: May 11, 2015
14.2K
Pulmonary hypertension - the latest updates for physicians.
Ruta Virsinskaite1, Nina Karia1, Tushar Kotecha1
1National Pulmonary Hypertension Service, Royal Free London NHS Foundation Trust, London, UK.
Clinical Medicine (London, England)
|September 29, 2023
Summary
Updated pulmonary hypertension (PH) guidelines lower diagnostic pressure thresholds and introduce new screening and referral pathways. Early diagnosis and specialist referral are crucial for improved patient outcomes.
Area of Science:
- Cardiology
- Pulmonology
- Internal Medicine
Background:
- Pulmonary hypertension (PH) affects approximately 1% of the population, increasing with age.
- Timely diagnosis and treatment are essential for improving patient prognosis and symptoms.
Approach:
- Summarizes recent updates to international PH diagnostic and management guidelines.
- Highlights revised haemodynamic thresholds and new diagnostic algorithms.
- Details updated screening indications and fast-track referral pathways for at-risk patients.
Key Points:
- The diagnostic threshold for PH is now a mean pulmonary artery pressure >20 mmHg.
- New algorithms facilitate earlier detection and referral to specialist PH centers.
- Fast-track referrals are established for high-risk patients, including those with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH).
Conclusions:
- General physicians play a critical role in the early identification and referral of PH patients.
- Adherence to updated guidelines ensures prompt and appropriate management.
- Revised guidelines aim to improve early diagnosis and outcomes for PH patients.
Related Concept Videos
01:30Pulmonary Hypertension: Classification and Pathogenesis
207
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
207
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
177
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
177
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
190
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
190
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
203
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
203
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
191
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
191
01:16Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
249
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
249